Physician profile
Alyssa Doyle
NPI 1215528310
$11,163.95
in general payments reported to CMS, 2019-2025
23 companies · $7,849 in 2025
The $7,849 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.04 · 2022: $1,912 · 2023: $230 · 2024: $1,142 · 2025: $7,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,264 · Travel and Lodging: $3,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,263.69 |
| Travel and Lodging | $3,958.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $4,107.74 | 2025 | Evoke |
| Boston Scientific Corporation | $3,810.87 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept Rf Probe |
| Globus Medical, INC. | $1,225.15 | 2025 | Senza, Vyrsa V1 |
| Nevro Corp. | $530.68 | 2023-2024 | Senza |
| Abbvie INC. | $269.97 | 2022-2025 | |
| Horizon Therapeutics Plc | $269.30 | 2022 | |
| Nalu Medical, INC. | $189.51 | 2023-2025 | Nalu Neurostimulation System |
| Painteq LLC | $155.93 | 2024 | Painteq |
| Novo Nordisk INC | $123.50 | 2024 | Wegovy |
| Neurelis, INC. | $64.36 | 2024-2025 | Valtoco |
| Alnylam Pharmaceuticals INC. | $61.58 | 2023-2024 | Amvuttra |
| Takeda Pharmaceuticals U.S.A., INC. | $57.46 | 2024-2025 | Hyqvia |
| Ucb, INC. | $41.79 | 2025 | Nayzilam |
| Spinal Simplicity, LLC | $35.70 | 2025 | Ha Minuteman G3-R |
| Pfizer INC. | $33.90 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $32.64 | 2025 | Cervical-Stim |
| Forte Bio-Pharma LLC | $30.65 | 2024 | Prolate, Nalocet |
| Octapharma USA, INC. | $28.53 | 2024 | Panzyga |
| Averitas Pharma INC. | $27.85 | 2024 | Qutenza |
| Valinor Pharma, LLC | $20.91 | 2025 | Movantik |
| Biodelivery Sciences International, INC. | $15.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.15 | 2024 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.